[{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSN Labs Launches Generic Cangrelor, a New Drug for PCI To Reduce Risk of MI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Cangrelor
KENGREAL (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce risk of MI, repeat coronary revascularization, and stent thrombosis (ST) in patients.
Company rolled out the first generic version of Cangrelor is an intravenous platelet P2Y12 antagonist ) used to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis.